A bladder ultrasound gives providers clues about how the bladder expands and holds urine. This article lists conditions ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) in Saudi Arabia has entered a five-year partnership with the ...

Enlarged prostate is a common health issue for men over 50, causing urinary problems due to prostate enlargement compressing the urinary passage. Earl ...

BHUBANESWAR: Ipsita Singh was experiencing recurring back pain, and multiple visits to an orthopedician did not show any ...

Bladder neck descent (BND) is prevalent among female runners who complain of stress urinary incontinence (SUI), which ...

The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat a type of urinary tract ...

Botox (botulinum toxin A) can be injected into the bladder wall to relax or paralyze the detrusor muscle. It is FDA-approved for OAB. The ideal dose of Botox for OAB is 100 units. Higher doses work ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

The setback in bladder cancer is a small disappointment, representing less than 10% of sales compared with 90% in breast cancer, TD Securities analyst Tyler Van Buren wrote in a note to clients. Van ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year. Gilead ...